Affinnova, Inc.

Affinnova adds $6 million in B round from Flagship Ventures

Affinnova adds $6 million in B round from Flagship Ventures

July 9, 2003

Cambridge, Mass. - July 9, 2003 - Affinnova, a leading provider of product design, development, and testing solutions, announced today that it has completed a $6 million Series B round of financing led by Flagship Ventures. This latest financing round is expected to accelerate the market penetration of Affinnova's solutions coming on the heels of a six-month period when the Company recorded revenue growth of more than 120% over prior year.

EXACT Sciences

Exact Sciences reaches $15 million milestone

Exact Sciences reaches $15 million milestone

August 13, 2003

Exact Sciences Corp. of Marlborough said it has achieved the $15 million milestone associated with the national commercial availability of PreGen-Plus, which is intended for early detection of colorectal cancer.

This is the second $15 million milestone achieved in connection with the licensing agreement Exact Sciences and Laboratory Corp. of America Holdings entered into in June 2002. PreGen-Plus is Exact Sciences' proprietary DNA-based stool assay for the early detection of colorectal cancer.

Renovis

Renovis raises $45.0 million in private placement

Renovis raises $45.0 million in private placement

August 11, 2003

South San Francisco, California - August 11, 2003 - Renovis, a biopharmaceutical company focused on the discovery and development of drugs to treat neurological diseases and disorders, announced today the completion of its Series E Preferred Stock financing totaling $45.0 million. Easton Hunt Capital Partners led the financing, which included first-time investments from HealthCap, MDS Capital, Invus Group, CDIB BioScience Ventures, and others.

Carbon Design Systems

Introducing Carbon Design Systems, EDA company formed to solve the system validation problem

Introducing Carbon Design Systems, EDA company formed to solve the system validation problem

September 2, 2003

Carbon Design Systems announced today that it is delivering software products that enable system validation of hardware and software in an enterprise-wide environment. For the first time, critical software - drivers, firmware, and diagnostics - runs at KHz execution speed on the 'golden' RTL hardware model with cycle and register accuracy. This enables system and customer validation to occur much earlier than traditional methods. The Company also announced that it has raised over $5 million in funding from Boston-based Flagship Ventures and Commonwealth Capital.

Selventa

Genstruct Completes $6.5 Million Series A Financing

Genstruct Completes $6.5 Million Series A Financing

September 8, 2003

CAMBRIDGE, Mass. September 8, 2003 - Genstruct, a biological-mechanism discovery company, today announced the completion of $6.5M in Series A financing co-led by A. M. Pappas and Associates (Research Triangle Park, NC) and Flagship Ventures (Cambridge, MA). These funds will be used to expand Genstruct's technical and business teams, build intellectual property around the company's enabling technology, and conduct internal discovery programs. As a result of the financing, Art Pappas, Managing Partner of A. M. Pappas and Associates, has joined Genstruct's Board of Directors.

CGI Pharmaceuticals, Inc.

Cellular Genomics wins European patent for kinase technology

Cellular Genomics wins European patent for kinase technology

September 16, 2003

Branford, Conn.-based Cellular Genomics Inc. today announced that the European Patent Office has granted the company a patent that covers general methods for discovering enzyme inhibitors, as well as methods and compositions of a class of specific inhibitors of protein kinases, a major class of drug targets.
CGI was granted a U.S. patent for the same technology in May 2002.

Zalicus

CombinatoRx CEO named Innovator of the Year

CombinatoRx CEO named Innovator of the Year

September 25, 2003

Alexis Borisy honored by Technology Review, MIT's Magazine of Innovation, at the Emerging Technologies Conference

e-Dialog, Inc.

E-Dialog acquires Whitespeed's rich media e-mail division

E-Dialog acquires Whitespeed's rich media e-mail division

September 30, 2003

Adds top creative, technology capabilities from interactive shop

LEXINGTON, MA - September 30, 2003 - e-Dialog, the precision e-mail marketing innovator, has acquired the e-mail marketing business of top interactive agency Whitespeed, based in Santa Monica, CA. The acquisition consolidates e-DialogÕs role as a comprehensive provider of cutting-edge e-mail services, and includes Whitespeed's e-mail client relationships, creative rich media capabilities and staff.

AVEO Pharmaceuticals, Inc.

GenPath Pharmaceuticals Raises $42.7 Million In Series B Funding

GenPath Pharmaceuticals Raises $42.7 Million In Series B Funding

October 1, 2003

Cambridge, Mass. - October 1, 2003 - GenPath Pharmaceuticals, Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has raised $42.7 million in a Series B financing.

CGI Pharmaceuticals, Inc.

Cellular Genomics and Affymetrix form research collaboration to develop novel high-content drug screens

Cellular Genomics and Affymetrix form research collaboration to develop novel high-content drug screens

October 9, 2003

Branford, Conn. - October 9, 2003 - Cellular Genomics, Inc. (CGI), a chemical genetics based biopharmaceutical company, today announced that it has established a research collaboration with Affymetrix, Inc. the pioneer in creating breakthrough tools that are driving the genetic revolution. In the collaboration, CGI will use Affymetrix GeneChip(R) brand technology in conjunction with CGI's chemical genetics Analog Sensitive Kinase Allele (ASKA) technology for the development of unique high-content assays for kinase drug discovery.